Piper Jaffray analyst Danielle Brill noted that Momenta management said enrollment in the Phase 2 proof-of-concept trial for M281 in myasthenia gravis is going well and data are still anticipated by Q2 or Q3 of 2020 while M281's second and third clinical programs in other indications are also progressing. Preliminary results with Momenta's second clinical candidate, M254, are also expected in the first half of 2020, noted Brill, who said she "loves the set-up for 2020 with multiple value creating catalysts on the calendar." She maintains an Overweight rating and $35 price target on Momenta shares.